What is the clinical evidence from this study?

Study design: Other. Population: Metabolic dysfunction-associated steatotic liver disease (MASLD) (n=269). Intervention: LASSO regression risk prediction models. Primary outcome: Accuracy for distinguishing simple steatosis (SS) samples from hepatocellular carcinoma (HCC) samples.

March 1, 2025Open Access

Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD)

Key Result

A 14-gene LASSO regression model accurately distinguished simple steatosis from hepatocellular carcinoma with an accuracy of 0.984, identifying CYP7A1 and TNFRSF12A as prognostic markers.

Structured PICO

Population

Transcriptomic data from human liver samples across five stages of MASLD (healthy liver n=44, obese liver n=27, simple steatosis n=34, MASH n=111, MASH-associated HCC n=53) from GEO databases, along with additional validation cohorts and STAM mouse models.

Intervention

Bioinformatic analysis using WGCNA and LASSO regression to identify gene expression patterns and develop risk prediction models

Outcome

Differentially expressed genes and predictive accuracy of LASSO regression models for MASLD occurrence and progressionsurrogate

Bioinformatic analysis identified distinct gene expression patterns and developed robust LASSO-based risk prediction models for the occurrence and progression of MASLD.

Limitations

MASLD does not exclusively result from obesity, which was the primary focus of the study.
Inability to obtain additional patient samples for assessing the model's capacity to predict the progression of MASLD to HCC.

Abstract

The global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise, primarily driven by the escalating obesity epidemic worldwide. MASLD, a spectrum of liver disorders, can progress to more severe conditions, metabolic dysfunction-associated steatohepatitis (MASH), ultimately culminating in hepatocellular carcinoma (HCC). Given the complex nature of MASLD, there is an urgent need to develop robust risk prediction models and design specialized cancer screening initiatives tailored specifically for individuals with MASLD. This study aimed to identify genes exhibiting trending expression patterns that could serve as potential biomarkers or therapeutic targets. Our approach involved analyzing expression patterns across the five stages of MASLD development and progression. Notably, we introduced an innovative two-phase classification-MASLD occurrence and MASLD progression-instead of categorizing differentially expressed genes (DEGs) into multiple types. Leveraging LASSO regression models, we demonstrated their relatively strong capability to predict and distinguish both MASLD occurrence and progression. Furthermore, our analysis identified CYP7A1 and TNFRSF12A as significantly associated with the prognosis of MASLD progressing to HCC. These findings contribute to the understanding of gene expression dynamics in MASLD and may pave the way for the development of effective prognostic tools and targeted therapies in the realm of liver disease.

Bookmark

View Full Paper